Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

BioNTech and Duality Biologics Team Up to Develop ADC Drug Candidates

BioNTech and Duality Biologics Team Up to Develop ADC Drug Candidates

BioNTech and China-based Duality Biologics have inked a licensing and collaboration deal to develop two antibody-drug conjugates (ADCs).

ADCs combine antibodies and their targeting abilities with either chemotherapy or other anticancer agents.

Under the terms of the partnership, BioNTech will gain access to Duality Biologics’ lead candidate DB-1303, a topoisomerase-1 inhibitor-based ADC aimed towards human epidermal growth factor receptor 2 (HER2), which is expressed in several cancers, including breast, bladder, pancreatic, ovarian and stomach cancers.

DB-1303 has shown potent antitumor activity in both HER2-positive and HER2-low tumor models, the companies said. The FDA has granted Fast Track Designation to DB-1303 and the drug candidate is being evaluated in a phase 2 clinical trial in HER2-expressing advanced solid tumors.

The partnership will also give BioNTech access to DB-1311, a second topoisomerase-1 inhibitor-based ADC candidate that has potential in a range of cancers.

Duality Biologics will receive upfront payments totaling $170 million and is eligible for potential milestone payments of more than $1.5 billion. 

BioNTech will gain rights to develop, manufacture and commercialize the two ADCs globally except in greater China.

April 10, 2023

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies